Welcome To The 300 Club HUB On AGORACOM

We may not make much money, but we sure have a lot of fun!

Free
Message: 6 Growth Stocks that will outlast a Bear Market
 

 

 

6 Growth Stocks That Will Outlast a Bear Market

By Mark Kolakowski | July 12, 2017 — 6:00 AM EDT
              
 
 
Add To Watchlist
Amazon.com Inc
AMZN
1,005.03
+1.10%
Created with Highstock 4.2.6
 
Facebook Inc
FB
158.23
+1.91%
Created with Highstock 4.2.6
 
Alibaba Grp Shs Sponsored American Deposit Share Repr 1 Sh
BABA
148.08
+1.56%
Created with Highstock 4.2.6
 
Illumina Inc
ILMN
173.16
+0.01%
Created with Highstock 4.2.6
 

Investors concerned about the bull market's longevity are focusing more acutely than ever on whether their stock portfolios can continue to generate strong returns. One successful approach may be buying growth stocks for the long term - at a discount - that will dominate the digital revolution sweeping areas from consumer goods to medicine to entertainment to autos. By long term, we mean holding a stock for seven years on average.

Beating 98% of Large Cap Funds

By doing just that, the Baron Fifth Avenue Growth Fund (BFTHX) is up over 25% so far in 2017, outperforming not only its benchmark, the Russell 1000 Growth Index, but also 98% of large cap growth funds, according to data from Morningstar Inc. cited by Barron's. Fund manager Alex Umansky employs a mix of growth and value investing techniques, and seeks companies that are likely to "dominate their industries in the digital revolution," as Barron's puts it. Umansky's six favorite stocks right now are: online merchant Amazon.com Inc. (AMZN

Add To Watchlist
Amazon.com Inc
AMZN
1,005.03
+1.10%
Created with Highstock 4.2.6
 
), social networking leader Facebook Inc. (FB
Add To Watchlist
Facebook Inc
FB
158.23
+1.91%
Created with Highstock 4.2.6
 
), Chinese online merchant Alibaba Group Holding Ltd. (BABA
Add To Watchlist
Alibaba Grp Shs Sponsored American Deposit Share Repr 1 Sh
BABA
148.08
+1.56%
Created with Highstock 4.2.6
 
), Chinese travel booking service Ctrip.com International Ltd. (CTRP
Add To Watchlist
Ctrip.com Intl Shs Sponsored American Deposit Shares Repr 1/8 th Sh
CTRP
56.07
+2.24%
Created with Highstock 4.2.6
 
), biotech firm Regeneron Pharmaceuticals Inc. (REGN
Add To Watchlist
Regeneron Pharmaceuticals Inc
REGN
494.54
+0.52%
Created with Highstock 4.2.6
 
) and genetic research company Illumina Inc. (ILMN
Add To Watchlist
Illumina Inc
ILMN
173.15
0.00%
Created with Highstock 4.2.6
 
). Umansky recently added cutting-edge electric car maker Tesla Inc. (TSLA
Add To Watchlist
Tesla Inc
TSLA
328.30
+0.33%
Created with Highstock 4.2.6
 
) to his portfolio, Barron's adds.

 

Riding the Digital Wave

Umansky says that his largest holdings are "mutiyear growth stocks" such as Amazon.com, Facebook and Alibaba, according to Barron's. Facebook, he notes, benefits from the movement of advertising budgets toward the Internet. Leading online sellers of broad categories of merchandise, such as Amazon.com and Alibaba, meanwhile, are gaining from consumers' increased desire for shopping convenience. (For more, see also: Why Investors in Retailers May Bleed Even More.)

Amazon.com also "has a tremendous lead" in cloud computing technology, a multi-trillion-dollar business that represents a "multiyear paradigm shift in computing," Umansky tells Barron's. In its original business, online retailing, Amazon.com captures a stunning 60 cents from each incremental dollar spent on e-commerce in the U.S., Umansky says.

Similarly, Alibaba is the leading cloud services provider in China, Umansky says. It also is building a one-stop-shopping financial services company and has an online payment service with 450 million users, he adds.

Alibaba often is described as China's Amazon.com, and Ctrip.com is its version of The Priceline Group Inc. (PCLN

Add To Watchlist
The Priceline Group Inc
PCLN
1,944.86
+0.81%
Created with Highstock 4.2.6
 
), Umansky tells Barron's. As China becomes more prosperous, its growing middle class is bound to spend yet more on travel and tourism spending. The Chinese already lead the world in spending over $170 billion annually on travel abroad, according to Umansky.

 

Digitizing Medicine

There are now about 230,000 ongoing clinical trials for drugs in the U.S., up from about 30,000 a decade ago, Umansky tells Barron's. Meanwhile, using DNA sequencing to select candidates for these clinical trials increases their probabilities of success "exponentially," Umansky adds. About 60% of the gene-sequencing equipment used worldwide is manufactured by Illumina, and this equipment is used in roughly 90% of the gene-sequencing tests performed across the globe, he says. Illumina's market value is now over ten times what it was five and half years ago, and Umansky expects another ten-fold increase during the next five to ten years.

Digitization is shortening the innovation cycle in biotechnology, Umansky observes. Regeron is his top pick in this area, and he notes that the stock has roughly doubled in price since he purchased it in 2014.

Umansky's Method

As mentioned, Umansky looks for stocks trading at least 20% below their intrinsic value, Barron's says. For a more detailed discussion of his philosophy, see his first quarter 2017 letter to shareholders. Per this document, a company's growth rate is one of the variables that his team uses in computing intrinsic value.

Umansky believes that long-term investors have increasing opportunities to profit as the markets become more focused on the short term, per Barron's. Accordingly, he holds stocks for an average of seven years, and has an annual portfolio turnover rate of only 16%. He also tells Barron's that he does not try to predict the market, Federal Reserve actions or election results. Instead, he looks for "the most competitively advantaged companies" for the long run, as he was quoted by Barron's. While Tesla does not fit his value criteria, Umansky bought it based on unique competitive advantages coming out of its technology.




Share
New Message
Please login to post a reply